Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, et al
[DOI] [PubMed] [Google Scholar] 399
Weighted bivariate linear regression analysis assessed score differences across demographics and health conditions separately for PROMIS-8a short form and EORTC QLQC-30 CF subscale
This triple mechanism produces greater weight loss, potentially better metabolic improvements, and additional effects like increased energy expenditure from glucagon activation
News provided by Eli Lilly and Company May 21, 2026, 06:45 ET In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving 30% weight loss, a level long associated with bariatric surgery Individuals with a baseline BMI 35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks At the 4 mg dose, reached with only a single escalation step, participants lost an average of 47.2 lbs (19.0%) at 80 weeks with a lower observed discontinuation rate due to adverse events vs
Reduced caloric intake from appetite suppression can contribute to fatigue, as can the metabolic adjustments your body makes in response to GLP-1 receptor activation
